Testing effectiveness (Phase 2)Ended earlyNCT04160052
What this trial is testing
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+2 more
M.D. Anderson Cancer Center 51